Bosulif (Bosutinib) Copay Assistance & Financial Help

Generic bosutinib is available now and can cost less than brand-name Bosulif. The list price (AWP) is roughly $890 per 400 mg or 500 mg tablet for brand Bosulif, versus about $792 (400 mg) and $742 (500 mg) for generic bosutinib. List price is not what you pay. With insurance and copay assistance, eligible patients MAY pay $0. QuickRx gives you a personalized cost estimate based on your plan. Call (917) 830-2525.

Yes. Generic bosutinib is FDA-approved and available, and QuickRx dispenses it. Generic bosutinib contains the same active ingredient at the same strength as brand-name Bosulif and works the same way in the body. It can cost less than brand-name Bosulif, which may lower your copay, especially under Medicare Part D.

Bosulif (bosutinib) copay assistance is help that lowers what you pay out of pocket for your CML medication. QuickRx enrolls eligible patients in manufacturer copay cards, foundation grants, and patient assistance programs, and dispenses generic bosutinib to reduce cost. Enrollment support is free, and eligible patients MAY pay $0.

Eligibility depends on your insurance. Commercially insured patients may qualify for the manufacturer copay card. Medicare and Medicaid patients may qualify for foundation grants. Uninsured patients may qualify for patient assistance programs based on income. QuickRx reviews your situation and identifies every program you qualify for. Call (917) 830-2525 to start.

Most CML patients can afford Bosulif through a combination of generic bosutinib and copay assistance. Commercially insured patients can use manufacturer copay cards, Medicare and Medicaid patients can apply for foundation grants, and uninsured patients may qualify for patient assistance programs. QuickRx enrolls you in every program you qualify for at no charge. Eligible patients MAY pay $0.

Savings vary by insurance type and the programs you qualify for. Manufacturer copay cards can significantly reduce out-of-pocket costs for commercially insured patients. Foundation grants help Medicare and Medicaid patients with costs their plan does not cover. Choosing generic bosutinib may lower your cost further. QuickRx works to stack every available benefit, and eligible patients MAY pay $0.

A Bosulif copay card is a manufacturer savings program for commercially insured patients that lowers your monthly out-of-pocket cost, sometimes to $0 or a minimal copay. To qualify you generally need active commercial insurance (not Medicare or Medicaid), a valid prescription, and U.S. residency. QuickRx handles the enrollment for free.

No. Federal law prohibits Medicare beneficiaries from using manufacturer copay cards. QuickRx instead connects Medicare patients to independent foundation grants and patient assistance programs designed for government-insured patients. Generic bosutinib may also be more affordable under Medicare Part D.

Yes. Generic bosutinib typically costs less than brand-name Bosulif and is FDA-approved as bioequivalent, so it works the same way in your body. Generic medications usually sit on lower insurance formulary tiers with lower copays, which matters most for Medicare Part D patients. QuickRx dispenses both and can compare your cost for each.

Yes. Uninsured patients may qualify for manufacturer patient assistance programs that provide bosutinib at no cost or reduced cost based on household income. Generic bosutinib is also a lower-cost option. QuickRx evaluates your eligibility, completes the application, and coordinates with the manufacturer at no charge to you.

QuickRx provides free, end-to-end copay assistance enrollment. We evaluate your coverage, identify every program you qualify for, complete the paperwork, verify benefits, handle prior authorizations, and manage annual renewals. We dispense generic bosutinib, coordinate with your prescriber, and deliver nationwide. We never charge fees for this support. Call (917) 830-2525 to get started.

Bosulif (bosutinib) is a prescription medication used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It is a BCR-ABL tyrosine kinase inhibitor (TKI) that blocks the abnormal protein driving CML cell growth. It is approved for adults and pediatric patients 1 year and older who are newly diagnosed with chronic phase Ph+ CML, and for adults with chronic, accelerated, or blast phase Ph+ CML who are resistant to or intolerant of prior therapy.

Bosulif is taken by mouth once daily with food, and tablets are swallowed whole. The usual dose is 400 mg once daily for newly diagnosed chronic phase CML, or 500 mg once daily for CML resistant to or intolerant of prior therapy. If a dose is missed beyond 12 hours, skip it and resume the next day. For a full diet and food-timing guide, see our Bosulif and food guide.

The most common side effects include diarrhea, nausea, vomiting, abdominal pain, rash, fatigue, low blood cell counts, elevated liver enzymes, and headache. Diarrhea is very common, especially in the first few months. For a detailed breakdown and management tips, see our Bosulif side effects guide, and review general cancer-treatment side effect information from the Mayo Clinic. Always report serious symptoms to your healthcare provider.

Avoid grapefruit and grapefruit juice, which can raise bosutinib levels in your blood through their effect on the CYP3A4 enzyme. Strong CYP3A4 inhibitors and inducers should be avoided, and acid-reducing medications like PPIs can lower absorption. Tell your pharmacist about every medication and supplement you take. Our food and diet guide covers this in detail.

Based on its mechanism and animal data, bosutinib may harm an unborn baby. Pregnancy status should be verified before starting treatment. Patients who can become pregnant should use effective contraception during treatment and for 2 weeks after the last dose, and breastfeeding is not recommended during treatment and for 2 weeks after. Talk to your healthcare provider before starting if you are pregnant, planning a pregnancy, or breastfeeding.